Earum Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2022. For the fourth quarter, the company reported sales was INR 47.38 million. Revenue was INR 101.58 million. Net loss was INR 7.16 million. Basic loss per share from continuing operations was INR 0.12. Diluted loss per share from continuing operations was INR 0.12.
For the full year, sales was INR 210.36 million compared to INR 410.84 million a year ago. Revenue was INR 287.39 million compared to INR 500.16 million a year ago. Net income was INR 22.24 million compared to INR 0.882 million a year ago. Basic earnings per share from continuing operations was INR 0.36 compared to INR 0.014 a year ago. Diluted earnings per share from continuing operations was INR 0.36 compared to INR 0.014 a year ago.